Delving into the Latest Updates on Applied Molecular Evolution, Inc. with Synapse

概览

关联

3

项与 Applied Molecular Evolution, Inc. 相关的药物

AME-527

靶点

TNF-α

作用机制

TNF-α抑制剂

在研机构-

原研机构

Applied Molecular Evolution, Inc.

在研适应症-

非在研适应症

炎症性肠病 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

AME-359

靶点-

作用机制-

在研机构-

原研机构

Applied Molecular Evolution, Inc.

在研适应症-

非在研适应症

可卡因相关疾病

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

Ocaratuzumab

靶点

CD20

作用机制

CD20抑制剂 [+3]

在研机构-

原研机构

Applied Molecular Evolution, Inc.

在研适应症-

非在研适应症

CD20阳性B细胞淋巴瘤 [+2]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

2

项与 Applied Molecular Evolution, Inc. 相关的临床试验

NCT00689507

/ Completed临床1期

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.

开始日期2008-03-01

申办/合作机构

Applied Molecular Evolution, Inc.

[+1]

NCT00354926

/ Completed临床1期

Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.

开始日期2006-07-01

申办/合作机构

Applied Molecular Evolution, Inc.

100 项与 Applied Molecular Evolution, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Applied Molecular Evolution, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 Applied Molecular Evolution, Inc. 相关的文献（医药）

Antibody Phage Display

Screening of Phage-Expressed Antibody Libraries by Capture Lift

Review

作者: Watkins, Jeffry D

A review which describes a modified form of the filter-lift assay, designated capture lift, in which phage-expressed soluble Fabs are selectively captured on the nitrocellulose, considerably enhancing the signal of the assay.The nitrocellulose filters are coated with an antibody (Ab) capture reagent, i.e., a polyclonal anti-κ-chain Ab, and the remaining protein-binding sites are blocked prior to performing the plaque lift.The selective binding of phage-expressed Fab, together with the reduced binding of unrelated bacterial proteins, improve the sensitivity of the assay.For the rapid one-step identification of higher-affinity Abs presenting complex Fab libraries, the capture-lift screen can be used by probing the filters with antigen (Ag) at concentrations below the K_d of the Ab-Ag interaction.The increased sensitivity and normalization of the amount of Fab bound on the nitrocellulose in the capture-lift assay increases the utility of filter-lift screening, allowing broader applications in both the discovery and the engineering of phage-expressed Fabs.

Extreme product development: A case study

作者: Myers, Jill A.

Small companies face many hurdles in producing biotherapeutics for clin. trials.These include (but are not limited to) shortages of experience, resources and time.This is especially true for a biotechnol. company immersed in development and production for the first time.Addnl., a small company must decide between contract manufacturing or development of inhouse capabilities.The use of "platform" or "generic" process development has generated much discussion in the industry.However even in the platform-friendly realm of therapeutic antibodies, diversity of sequence and structure can provide challenges.A case study will be presented for an antibody produced for a phase I clin. trial by Applied Mol. Evolution (AME) in which multiple activities were successfully completed in parallel in less than two years.Development infrastructure was created from scratch, including building new groups (Process Sciences, Production, Quality and Clin. Affairs); designing and constructing an inhouse GMP facility; developing and transferring a robust process and characterizing and releasing clin. material.Lessons learned and tech. and non-tech. reasons behind this achievement will be presented.

100 项与 Applied Molecular Evolution, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Applied Molecular Evolution, Inc. 相关的转化医学

登录后查看更多信息